Table 3:
All Subjects (N=199) | Anxiety positive only (N=71) | Depression positive only (N=45) | Anxiety & depression positive (N=83) | P-value* | |
---|---|---|---|---|---|
Age (yrs) (mean SD) | 42.9 ± 15.5 | 41.4 ± 15.4 | 44.8 ± 13.7 | 43.2 ± 16.4 | 0.50 |
Female | 114 (57.3%) | 45 (63.4%) | 24 (53.3%) | 45 (54.2%) | 0.43 |
Race | 0.40 | ||||
White or Caucasian | 169 (84.9%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
Black or African American | 24 (12.1%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
Other | 6 (3.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
Hispanic/Latino | 6 (3.0%) | 5 (7.0%) | 0 (0.0%) | 1 (1.2%) | 0.04 |
Opt-in to research | 154 (77.4%) | 49 (69.0%) | 34 (75.6%) | 71 (85.5%) | 0.05 |
Currently on antidepressant medication?** | 87 (43.7%) | 25 (35.2%) | 18 (40.0%) | 44 (53.0%) | 0.07 |
Current treatment by psychiatrist or therapist? | 61 (30.7%) | 11 (15.5%) | 13 (28.9%) | 37 (44.6%) | <0.001 |
Prior psychiatric hospitalization | 48 (24.1%) | 14 (19.7%) | 12 (26.7%) | 22 (26.5%) | 0.56 |
chi square test; chi square p value shown at top of category label for categorical variables having more than 2 categories
SSRI, SNRI, mirtazapine, bupropion, or buspirone